Alzheimer’s Disease is a slow, fatal disease of the brain that affects 564,000 Canadians. There is still no known cure. Though biomarkers for the disease exist well before clinical symptoms are present, they are hard to detect, meaning Alzheimer’s is often diagnosed when it is already too late. To address the diagnosis gap, early screening must be widespread. RetiSpec is a Toronto-based medical device startup company developing a non-invasive eye scanner for early detection of Alzheimer’s Disease pathology years before symptoms occur. Early detection enables clinicians to intervene with emerging therapeutics early, when there is a chance of impacting the disease.